ranolazine has been researched along with Death, Sudden, Cardiac in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Furtado, JD; Guo, J; Morrow, DA; Mozaffarian, D; O'Donoghue, ML; Sabatine, MS; Scirica, BM; Zelniker, TA | 1 |
| Al-Khatib, SM; Allen LaPointe, NM; Curtis, LH; Hammill, BG; Mi, X; Pokorney, SD | 1 |
| Belardinelli, L; Kanas, AF; Morrow, DA; Nearing, BD; Nieminen, T; Pagotto, VP; Pegler, JR; Scirica, BM; Sobrado, MF; Tavares, C; Umez-Eronini, AA; Verrier, RL | 1 |
| Freudenberger, R; Levin, V; Martinez, MW; Nanda, S | 1 |
| Patton, KK | 1 |
| Belardinelli, L; Braunwald, E; Hedgepeth, CM; Karwatowska-Prokopczuk, E; Morrow, DA; Qin, J; Scirica, BM; Spinar, J; Verheugt, FW; Wang, W | 1 |
| Madias, JE | 1 |
| Ayalloore, SG; LeLorier, P | 1 |
| Belardinelli, L; Cheng, ML; Karwatowska-Prokopczuk, E; Schwartz, PJ; Wang, W; Zeng, D | 1 |
3 trial(s) available for ranolazine and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36.
Topics: Acute Coronary Syndrome; Biomarkers; Cardiovascular Agents; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Fatty Acids, Omega-3; Female; Humans; Incidence; Male; Middle Aged; Ranolazine; Risk Assessment; Risk Factors; United States | 2021 |
Relation of T-wave alternans to mortality and nonsustained ventricular tachycardia in patients with non-ST-segment elevation acute coronary syndrome from the MERLIN-TIMI 36 trial of ranolazine versus placebo.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Death, Sudden, Cardiac; Electrocardiography; Enzyme Inhibitors; Female; Heart Conduction System; Humans; Male; Middle Aged; Piperazines; Placebos; Predictive Value of Tests; Ranolazine; Risk Factors; Tachycardia, Ventricular; Treatment Outcome | 2014 |
Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thr
Topics: Acetanilides; Acute Coronary Syndrome; Death, Sudden, Cardiac; Electrocardiography; Enzyme Inhibitors; Follow-Up Studies; Humans; Incidence; Myocardial Infarction; Piperazines; Placebos; Prognosis; Proportional Hazards Models; Ranolazine; Risk Factors; Tachycardia, Ventricular; Thrombolytic Therapy; Ventricular Premature Complexes | 2010 |
6 other study(ies) available for ranolazine and Death, Sudden, Cardiac
| Article | Year |
|---|---|
Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases, Factual; Death, Sudden, Cardiac; Defibrillators, Implantable; Electric Countershock; Female; Humans; Logistic Models; Male; Medicare Part D; Mexiletine; Ranolazine; Sodium Channel Blockers; Sotalol; Tachycardia, Ventricular; United States | 2017 |
Ranolazine--treatment of ventricular tachycardia and symptomatic ventricular premature beats in ischemic cardiomyopathy.
Topics: Acetanilides; Anti-Arrhythmia Agents; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Coronary Artery Bypass; Coronary Artery Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Dyspnea; Enzyme Inhibitors; Humans; Male; Middle Aged; Piperazines; Ranolazine; Stroke Volume; Tachycardia, Ventricular; Treatment Outcome; Ventricular Premature Complexes | 2010 |
The riddle of nonsustained ventricular tachycardia and sudden cardiac death: are we approaching a solution?
Topics: Acetanilides; Death, Sudden, Cardiac; Defibrillators, Implantable; Enzyme Inhibitors; Humans; Piperazines; Predictive Value of Tests; Ranolazine; Risk Factors; Tachycardia, Ventricular; United States | 2010 |
Letter by Madias regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-
Topics: Acetanilides; Acute Coronary Syndrome; Death, Sudden, Cardiac; Electrocardiography; Enzyme Inhibitors; Heart Rate; Humans; Myocardial Infarction; Myocardial Ischemia; Piperazines; Predictive Value of Tests; Ranolazine; Risk Factors; Stroke Volume; Tachycardia, Ventricular; Thrombolytic Therapy | 2011 |
Letter by Ayalloore and LeLorier regarding article, "Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the Metabolic Efficiency with Ranolazine for Less Isc
Topics: Acetanilides; Acute Coronary Syndrome; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Electrocardiography; Enzyme Inhibitors; Heart Rate; Humans; Myocardial Infarction; Myocardial Ischemia; Piperazines; Predictive Value of Tests; Ranolazine; Risk Factors; Stroke Volume; Tachycardia, Ventricular; Thrombolytic Therapy | 2011 |
The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine.
Topics: Acetanilides; Acute Coronary Syndrome; Aged; Cardiovascular Agents; Death, Sudden, Cardiac; Electrocardiography; Female; Humans; Incidence; Kaplan-Meier Estimate; Long QT Syndrome; Male; Multivariate Analysis; Piperazines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Ranolazine; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2013 |